Observational studyJournal of medicine and life2022
Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity.
Observational study in Journal of medicine and life, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Effectiveness and Safety of Hair Growth Formulation ContainingJournal of evidence-based integrative medicineTrial
- Article
- Symptom Trajectories and Long-Term Sequelae of COVID-19: A Matched Case-Control Study with Population-Based Controls.Journal of clinical medicine · 2026Article
- Overview of Short Peptides for Hair Loss.Biomedicines · 2026Review
- Ex vivo detection of SARS CoV 2 spike protein in human hair follicles and potential link to telogen effluvium.Scientific reports · 2025Article
- Post-COVID Hair Loss in the Indian Subcontinent: Clinical Patterns and Association with Disease Severity.Dermatology practical & conceptual · 2025Article
- Limited Awareness of Long COVID Despite Common Experience of Symptoms Among African American/Black, Hispanic/Latino, and Indigenous Adults in Arizona.Journal of racial and ethnic health disparities · 2025Article
- Patients' knowledge, attitude, and practice regarding alopecia: a cross-sectional study in Hebei, China.BMC public health · 2025Article
- Incidence of alopecia and hair loss among female active component service members, 2010-2022.MSMR · 2024Article
- Post Covid telogen effluvium: the diagnostic value of serum ferritin biomarker and the preventive value of dietary supplements. a case control study.Archives of dermatological research · 2024Article
- Calcium channel blockers may reduce the development of long COVID in females.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Hair disorders associated with post-COVID-19 infection in females: a cross-sectional study.Irish journal of medical science · 2024Article
- Comparison of Telogen Effluvium Incidence in Hospitalized and Outpatient Settings after Recovery from COVID-19.Iranian journal of medical sciences · 2024Article
- A Cross-Sectional Study on Post-Coronavirus Disease (COVID-19) Hair Loss at a Tertiary Care Hospital.Dermatology practical & conceptual · 2023Article
- SARS-CoV-2 Infection-A Trigger Factor for Telogen Effluvium: Review of the Literature with a Case-Based Guidance for Clinical Evaluation.Life (Basel, Switzerland) · 2023Review
- Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients.Frontiers in public health · 2023Article
- Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a concerning global pandemic. Common manifestations are fever and respiratory symptoms. In addition, recent studies reported dermatological manifestations as extrapulmonary signs. One of these is telogen effluvium which is related to post COVID-19 comorbidities. The aim of this study was to assess the prevalence of telogen effluvium among COVID-19 patients. This observational cross-sectional study included 198 patients who were admitted for COVID-19. The PCR test was performed to detect positive cases. After discharge, all patients were interviewed about hair loss. Of these patients, 79 were male (39.9%), and 119 were female (60.1%). The age ranged from 18 to 85 years old. 48 patients showed hair loss. Telogen effluvium (TE) is one of the consequences of the COVID-19 pandemic. COVID-19 leads to more medications and stress situations, which trigger TE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.